{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T14:55:02Z","timestamp":1781708102195,"version":"3.54.5"},"reference-count":23,"publisher":"Norwegian Medical Association","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tidsskr Nor Legeforen","Tidsskriftet"],"DOI":"10.4045\/tidsskr.21.0194","type":"journal-article","created":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T03:21:18Z","timestamp":1631071278000},"source":"Crossref","is-referenced-by-count":1,"title":["Kreftbehandling med isolert ekstremitetsperfusjon"],"prefix":"10.4045","volume":"141","author":[{"given":"Milan","family":"Spasojevic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony B.","family":"Mariathasan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Frich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d8yvind S.","family":"Bruland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stein G.","family":"Larsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Stoldt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2479","published-online":{"date-parts":[[2021,8,19]]},"reference":[{"key":"ref=1","doi-asserted-by":"crossref","unstructured":"Creech\u00a0O, Krementz\u00a0ET, Ryan\u00a0RF et al. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg 1958; 148: 616\u201332. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=13583933&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1097%2F00000658-195810000-00009","DOI":"10.1097\/00000658-195810000-00009"},{"key":"ref=2","unstructured":"Tsagozis\u00a0P, Brosj\u00f6\u00a0O, Skorpil\u00a0M. Preoperative radiotherapy of soft-tissue sarcomas: surgical and radiologic parameters associated with local control and survival. Clin Sarcoma Res 2018; 8: 19. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=30323920&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1186%2Fs13569-018-0106-x"},{"key":"ref=3","doi-asserted-by":"crossref","unstructured":"Nieweg\u00a0OE, Kroon\u00a0BB. Isolated limb perfusion with melphalan for melanoma. J Surg Oncol 2014; 109: 332\u20137. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=24421252&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1002%2Fjso.23558","DOI":"10.1002\/jso.23558"},{"key":"ref=4","doi-asserted-by":"crossref","unstructured":"Lienard\u00a0D, Ewalenko\u00a0P, Delmotte\u00a0JJ et al. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992; 10: 52\u201360. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1727926&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1200%2FJCO.1992.10.1.52","DOI":"10.1200\/JCO.1992.10.1.52"},{"key":"ref=5","doi-asserted-by":"crossref","unstructured":"Eggermont\u00a0AM, Schraffordt Koops\u00a0H, Klausner\u00a0JM et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg 1996; 224: 756\u201364. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8968230&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1097%2F00000658-199612000-00011","DOI":"10.1097\/00000658-199612000-00011"},{"key":"ref=6","doi-asserted-by":"crossref","unstructured":"Ahmed\u00a0AE, Hsu\u00a0TF, el-Azhary\u00a0RA et al. Tissue distribution and macromolecular interactions of 14[C-ring] melphalan in the rat. Cancer Chemother Pharmacol 1982; 8: 271\u20136. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7127659&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1007%2FBF00254049","DOI":"10.1007\/BF00254049"},{"key":"ref=7","doi-asserted-by":"crossref","unstructured":"Johansson\u00a0J, Kiffin\u00a0R, Andersson\u00a0A et al. Isolated limb perfusion with melphalan triggers immune activation in melanoma patients. Front Oncol 2018; 8: 570. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=30560089&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.3389%2Ffonc.2018.00570","DOI":"10.3389\/fonc.2018.00570"},{"key":"ref=8","doi-asserted-by":"crossref","unstructured":"de Wilt\u00a0JH, ten Hagen\u00a0TL, de Boeck\u00a0G et al. Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion. Br J Cancer 2000; 82: 1000\u20133. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10737379&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1054%2Fbjoc.1999.1032","DOI":"10.1054\/bjoc.1999.1032"},{"key":"ref=9","doi-asserted-by":"crossref","unstructured":"Moreno-Ramirez\u00a0D, de la Cruz-Merino\u00a0L, Ferrandiz\u00a0L et al. Isolated limb perfusion for malignant melanoma: systematic review on effectiveness and safety. Oncologist 2010; 15: 416\u201327. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=20348274&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1634%2Ftheoncologist.2009-0325","DOI":"10.1634\/theoncologist.2009-0325"},{"key":"ref=10","doi-asserted-by":"crossref","unstructured":"Cornett\u00a0WR, McCall\u00a0LM, Petersen\u00a0RP et al. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. J Clin Oncol 2006; 24: 4196\u2013201. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16943537&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1200%2FJCO.2005.05.5152","DOI":"10.1200\/JCO.2005.05.5152"},{"key":"ref=11","doi-asserted-by":"crossref","unstructured":"Madu\u00a0MF, Deken\u00a0MM, van der Hage\u00a0JA et al. Isolated limb perfusion for melanoma is safe and effective in elderly patients. Ann Surg Oncol 2017; 24: 1997\u20132005. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=28188500&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1245%2Fs10434-017-5803-9","DOI":"10.1245\/s10434-017-5803-9"},{"key":"ref=12","doi-asserted-by":"crossref","unstructured":"Hildebrandt\u00a0B, Wust\u00a0P, Ahlers\u00a0O et al. The cellular and molecular basis of hyperthermia. Crit Rev Oncol Hematol 2002; 43: 33\u201356. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12098606&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2FS1040-8428(01)00179-2","DOI":"10.1016\/S1040-8428(01)00179-2"},{"key":"ref=13","doi-asserted-by":"crossref","unstructured":"Wieberdink\u00a0J, Benckhuysen\u00a0C, Braat\u00a0RP et al. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 1982; 18: 905\u201310. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=6891640&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2F0277-5379(82)90235-8","DOI":"10.1016\/0277-5379(82)90235-8"},{"key":"ref=14","doi-asserted-by":"crossref","unstructured":"Grunhagen\u00a0DJ, de Wilt\u00a0JH, Graveland\u00a0WJ et al. Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb-threatening soft tissue sarcoma. Cancer 2006; 106: 1776\u201384. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16541435&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1002%2Fcncr.21802","DOI":"10.1002\/cncr.21802"},{"key":"ref=15","doi-asserted-by":"crossref","unstructured":"M\u00f6ller\u00a0MG, Lewis\u00a0JM, Dessureault\u00a0S et al. Toxicities associated with hyperthermic isolated limb perfusion and isolated limb infusion in the treatment of melanoma and sarcoma. Int J Hyperthermia 2008; 24: 275\u201389. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=18393005&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1080%2F02656730701805520","DOI":"10.1080\/02656730701805520"},{"key":"ref=16","doi-asserted-by":"crossref","unstructured":"Martin-Tellez\u00a0KS, van Houdt\u00a0WJ, van Coevorden\u00a0F et al. Isolated limb perfusion for soft tissue sarcoma: Current practices and future directions. A survey of experts and a review of literature. Cancer Treat Rev 2020; 88: 102058. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=32619864&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2Fj.ctrv.2020.102058","DOI":"10.1016\/j.ctrv.2020.102058"},{"key":"ref=17","doi-asserted-by":"crossref","unstructured":"Olofsson\u00a0R, Bergh\u00a0P, Berlin\u00a0O et al. Long-term outcome of isolated limb perfusion in advanced soft tissue sarcoma of the extremity. Ann Surg Oncol 2012; 19: 1800\u20137. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=22219068&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1245%2Fs10434-011-2196-z","DOI":"10.1245\/s10434-011-2196-z"},{"key":"ref=18","doi-asserted-by":"crossref","unstructured":"Deroose\u00a0JP, Eggermont\u00a0AM, van Geel\u00a0AN et al. Long-term results of tumor necrosis factor alpha- and melphalan-based isolated limb perfusion in locally advanced extremity soft tissue sarcomas. J Clin Oncol 2011; 29: 4036\u201344. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=21931039&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1200%2FJCO.2011.35.6618","DOI":"10.1200\/JCO.2011.35.6618"},{"key":"ref=19","unstructured":"Larkin\u00a0J, Chiarion-Sileni\u00a0V, Gonzalez\u00a0R et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 2019; 381: 1535\u201346. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=31562797&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1056%2FNEJMoa1910836"},{"key":"ref=20","doi-asserted-by":"crossref","unstructured":"Robert\u00a0C, Grob\u00a0JJ, Stroyakovskiy\u00a0D et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med 2019; 381: 626\u201336. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=31166680&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1056%2FNEJMoa1904059","DOI":"10.1056\/NEJMoa1904059"},{"key":"ref=21","unstructured":"Helsedirektoratet. Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppf\u00f8lging av maligne melanomer, 22.5.2020. https:\/\/www.helsebiblioteket.no\/retningslinjer\/maligne-melanomer Lest 21.6.2021."},{"key":"ref=22","unstructured":"Helsedirektoratet. Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppf\u00f8lging av sarkom, 10.4.2018. https:\/\/www.helsebiblioteket.no\/retningslinjer\/sarkomer\/ Lest 21.6.2021."},{"key":"ref=23","doi-asserted-by":"crossref","unstructured":"Noorda\u00a0EM, Vrouenraets\u00a0BC, Nieweg\u00a0OE et al. Isolated limb perfusion: what is the evidence for its use? Ann Surg Oncol 2004; 11: 837\u201345. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15313738&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1245%2FASO.2004.12.042","DOI":"10.1245\/ASO.2004.12.042"}],"container-title":["Tidsskrift for Den norske legeforening"],"original-title":[],"language":"no","deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T14:08:58Z","timestamp":1781705338000},"score":1,"resource":{"primary":{"URL":"https:\/\/tidsskriftet.no\/2021\/08\/klinisk-oversikt\/kreftbehandling-med-isolert-ekstremitetsperfusjon"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,19]]},"references-count":23,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,9,7]]}},"URL":"https:\/\/doi.org\/10.4045\/tidsskr.21.0194","relation":{},"ISSN":["0029-2001","0807-7096"],"issn-type":[{"value":"0029-2001","type":"print"},{"value":"0807-7096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,19]]}}}